tirzepatide approval Zepbound (tirzepatide) is the first and only FDA approved prescription medicine for moderate-to-severe OSA in adults with obesity Lilly's Weight-Loss Drug Approved in

Lilly NDC 0002-1484-80 Mounjaro (tirzepatide) injection 7.5 mg/0.5 mL Use one pen every week

This higher dose was not used in the study, and effectiveness compared to Mounjaro with this higher Ozempic dose may have been greater

Do not use the medicine with lot number NAR0074 and serial number 430834149057

The subgroup treated with the maximum dose of tirzepatide lost an average of 22.5% of their body weight (approximately 24 kg) and 63% of subjects lost at least 20% of their body weight

Integrated AI learning models to perform clerical tasks and give providers additional leverage to spend more time with patients and less on manual, administrative tasks